The MAPK Pathway Explained: Ras, RAF, MEK and ERK

Almost every claim that a peptide “promotes proliferation”, “drives repair” or “signals for growth” is, somewhere underneath, a claim about the MAPK pathway. It is one of the most studied signal-transduction routes in biology, it has approved medicines pointed at it, and it is also one of the most casually invoked — attached to compounds whose published literature never measured it.

This guide covers how the cascade actually works, what it does when it fires, why the duration of the signal matters more than its presence, and which research compounds have genuine ERK data behind them. On the last point the answer is mixed, and the mixed parts are stated plainly.

What a MAPK is

A mitogen-activated protein kinase is an enzyme that adds phosphate groups to other proteins, and the classic ones sit at the bottom of a three-layer relay. Reactome’s curated description of the family is precise about it: the classic cascades have three tiers of sequentially acting, activating kinases, where the kinase at the top phosphorylates dual-specificity MAPK kinase proteins, which in turn phosphorylate the MAPKs on a conserved Thr-X-Tyr motif in the activation loop.

Two naming conventions coexist. The numeric one — MAP3K, MAP2K, MAPK — reads off the tier. The older one — MAPKKK, MAPKK, MAPK — reads off what phosphorylates what. Neither is wrong, and older literature uses retired gene symbols too: MAPK3 was once PRKM3, MAP2K1 was PRKMK1, MAPK14 was CSBP1.

One detail is worth carrying forward because it explains a great deal of specificity: MAPKs are proline-directed. They phosphorylate serine or threonine in a P-X-S/T-P context. That constraint is why a kinase with hundreds of potential targets does not simply phosphorylate everything.

The Ras–RAF–MEK–ERK cascade

The canonical sequence starts outside the cell. A growth factor binds a receptor tyrosine kinase; the activated receptor recruits the adaptor Grb2, which binds the Ras exchange factor SOS through two SH3 domains — the association reported by Egan and colleagues in 1993. SOS then loads Ras with GTP. Ras-GTP recruits and activates a RAF kinase, RAF phosphorylates MEK1 and MEK2, and MEK phosphorylates ERK1 and ERK2.

The last step is the one worth getting exactly right, because the numbers in the literature look contradictory until you see why. ERK is activated by phosphorylation of two residues in its activation loop, a threonine and a tyrosine separated by one residue. Counted directly in the curated human sequences:

Three things fall out of that table. First, the branch-defining difference between ERK, p38 and JNK is literally one residue in the middle of the motif. Second, JNK1 needs two different upstream kinases, one per residue — a detail most summaries blur. Third, both phosphorylations are generally required: for p38 alpha, dual phosphorylation gives a far more active enzyme than the threonine alone, and tyrosine phosphorylation on its own yields an inactive enzyme.

And this is where the famous numbering confusion comes from. “Thr202/Tyr204” is ERK1 numbering. The equivalent ERK2 sites are Thr185/Tyr187. The standard laboratory antibody is named phospho-p44/42 MAPK (Thr202/Tyr204) and detects both proteins, which is exactly why ERK1’s numbers get applied to ERK2 in print. Rat ERK2, the numbering used in the 1991 paper that first mapped these sites, is Thr183/Tyr185 — a third set.

Three branches, and the fourth

The conventional teaching picture has three mammalian MAPK branches: ERK as the mitogenic one, p38 and JNK as the stress-activated ones. That framing is useful and incomplete. Reactome names four classic cascades — ERK1/2, p38, JNK and ERK5 — and records a separate class of atypical MAPKs, including ERK3, ERK4, ERK7 and NLK, which do not appear to follow the three-tier system at all.

The cleanest way to tell the branches apart is not by stimulus, which overlaps, but by which MAP2K sits above them — the right-hand column of the table above. There are also genuinely non-canonical routes: p38 alpha can be activated through tyrosine-323 phosphorylation by ZAP70 during T-cell receptor signalling, which is nothing like the textbook cascade.

This pathway is the intracellular counterpart to the receptor-level story in our guide to how peptide receptors and GPCRs work, and it runs in parallel with the second-messenger route covered in cyclic AMP and protein kinase A. Where cAMP carries a signal as a diffusible small molecule, MAPK carries it as a chain of phosphorylations.

What ERK does once it is on

Activated ERK phosphorylates substrates in the cytoplasm and, after translocating, in the nucleus. Four are well documented at primary sources:

• RSK (RPS6KA1). The 1988 paper that established it says so in its title: insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II.
• ELK1, an accessory factor for serum response factor, whose growth-factor-regulated transcriptional activation domain was characterised in 1993.
• c-Myc at Ser62. Phosphorylation of Ser62 is required for Ras-induced stabilisation of Myc, likely through ERK. The neighbouring Thr58 site is a GSK-3 target and depends on Ser62 being phosphorylated first — and Thr58 phosphorylation is associated with Myc degradation. Same protein, two sites, opposite consequences.
• c-Fos, which is both an output and, as the next section shows, the pathway’s own timer.

ERK also phosphorylates members of its own cascade. Those are feedback substrates, and they are the more interesting half of the story.

Feedback, and why duration matters

A cascade with amplification and no brake would be a one-shot device. The MAPK pathway has brakes at every level.

Phosphatases. MKP-1, the product of DUSP1, is itself an immediate-early gene product — the pathway induces its own off-switch. The classical MKP family runs to ten genes in mammals, in three subgroups with different localisations: DUSP1, DUSP2, DUSP4 and DUSP5 are nuclear, DUSP6, DUSP7 and DUSP16 cytoplasmic, and some, including DUSP8, DUSP9 and DUSP10, appear in both. Selectivity differs too — DUSP6 inactivates ERK1/2 but not JNK or p38, while DUSP10 acts on p38 and JNK. The authors of the review that catalogues this explicitly caution that reported specificities should be treated carefully, because many assays do not reflect in-vivo conditions, so the tidy table version is more confident than the data.

Direct feedback phosphorylation. ERK phosphorylates RAF1 at six serines — Ser29, Ser43, Ser289, Ser296, Ser301 and Ser642. All six require MEK signalling, which establishes the loop; hyperphosphorylation disrupts the Ras–Raf-1 interaction and desensitises Raf-1 to further stimulation. RAF1 mutants lacking those sites stay at the plasma membrane and remain persistently active. PP2A and the prolyl isomerase PIN1 reset Raf-1 for later rounds. ERK also phosphorylates SOS1, which weakens the Grb2–SOS1 interaction and throttles further Ras loading, and feeds back onto BRAF and MEK1.

Duration, not presence, encodes the outcome. This is the part that changes how claims should be read. In PC12 cells — a rat line, so this is cell biology, not a human finding — nerve growth factor produces sustained MAP kinase activation while epidermal growth factor produces transient activation, and the 1992 paper’s own title says sustained activation “may be required” for differentiation. That hedge was the authors’; it is worth keeping.

The mechanism came a decade later, and it is elegant. c-Fos acts as a sensor of ERK signal duration. Under a brief signal, ERK activity has decayed before c-Fos accumulates, and the unstable protein is degraded. Under a sustained signal, still-active ERK and RSK phosphorylate c-Fos at its C-terminus, which stabilises it and exposes an ERK docking site, permitting further phosphorylation. Mutating that docking domain breaks the sensor. So the same kinase, at the same amplitude, produces different fates depending only on how long it stays on — which is why “compound X activates ERK” is not, on its own, a statement about what the cell will do.

Why the MAPK pathway dominates cancer biology

This section is biology and regulatory history. Nothing in it is a treatment recommendation, and none of the compounds named is a research peptide or anything Pure Peptides Canada supplies.

In 2002, Davies and colleagues reported somatic BRAF missense mutations in 66 per cent of the malignant melanomas in their sample set, all within the kinase domain, with a single substitution accounting for about 80 per cent of them. They wrote that substitution as V599E. The curated human BRAF sequence puts valine at position 600, with glutamate-600 recorded as a cancer variant — so V599E and V600E are the same substitution, renumbered after the original reference sequence was found to be one residue short. Later large-scale sequencing established BRAF-mutant melanoma as one of four genomic subtypes, alongside RAS-mutant, NF1-mutant and triple-wild-type. We could not verify a current population-level percentage at an accessible primary source, so none is quoted here.

Three BRAF inhibitors and three MEK inhibitors have US approvals, each verifiable in the regulator’s own documents: vemurafenib (2011), dabrafenib (2013) and encorafenib (2018) at RAF; trametinib (2013), cobimetinib (2015) and binimetinib (2018) at MEK. The regulator’s own label language names the target as the RAS/RAF/MEK/ERK pathway.

And then the pathway does something that makes it a genuinely good teaching example. ATP-competitive RAF inhibitors suppress ERK signalling in BRAF-mutant cells but enhance it in cells with wild-type BRAF. Two 2010 papers published back to back established the mechanism: drug binding to one protomer of a RAF dimer inhibits that one while transactivating its drug-free partner. The effect requires active Ras, so it shows up in KRAS-mutant and RAS/RAF-wild-type cells and is minimal where BRAF V600E has made Ras activity irrelevant. In some xenografts it increased tumour growth. The regulatory record reflects the biology directly: these agents are labelled as not indicated in wild-type BRAF melanoma, and the approved BRAF inhibitors are indicated in combination with a MEK inhibitor. A pathway “inhibitor” whose effect inverts with genotype is about as clear a lesson in context-dependence as signal transduction offers.

Which research compounds actually have ERK data

MAPK and ERK appear constantly in research-compound writing. Here is what the primary literature supports, compound by compound. The concentrations below are exposures in culture medium, which is what every one of these experiments measured.

Three clarifications the table cannot carry.

The BPC-157 caveats. The single study was in one cell type at one time point. No Western blot confirms that the MEK inhibitor actually reduced phospho-ERK in the functional experiments, so that link is inferential. The paper calls that inhibitor an “ERK1/2 inhibitor” when it is in fact a MEK inhibitor acting upstream — so what the functional data show is MEK-dependence, not direct ERK involvement. And the BPC-157 was made in the authors’ own laboratory, with no third-party identity or purity documentation reported, which matters for anyone whose interest in these compounds begins with a certificate. Separately, a 2025 reply in the peer-reviewed literature argues that more than 80 per cent of indexed BPC-157 records carry the same two researchers as first or senior author, which the authors say limits generalisability; that is one side of a published disagreement, not a settled verdict, and it is reported here as such. There is also a widely cited 2017 paper that is routinely offered as BPC-157-and-ERK evidence; it measures VEGFR2 expression and the VEGFR2–Akt–eNOS route, not ERK, and citing it for ERK is simply an error. Our guide to reading a peptide study covers how to spot that kind of substitution.

TB-500 is not always thymosin beta-4. Thymosin beta-4 is the product of TMSB4X: a 43-residue actin-sequestering peptide once the initiator methionine is removed (the gene encodes 44 amino acids). “TB-500” is a trade name used both for synthetic full-length thymosin beta-4 and, by some suppliers, for short fragments of it, as our TB-500 guide explains. Unless the molecule in a vial is identified, the published thymosin-beta-4 literature cannot be transferred to a product sold as TB-500, which undercuts a large share of what circulates about the latter.

The melanocortin receptor is not KPV. There is real evidence that MC1R can couple to ERK: an alpha-MSH analogue significantly increased ERK phosphorylation in breast cancer lines and an MC1R-overexpressing system, with a MEK inhibitor as control. That is a receptor-level finding using an analogue, and it says nothing about KPV, the C-terminal tripeptide. Our guides to KPV and GHK-Cu cover what each compound’s literature does establish, and the NF-kB pathway is where the better-evidenced claims for both actually sit.

Seven things commonly got wrong

1. “V599E and V600E are different mutations.” They are the same substitution. The 2002 paper used V599E; the reference sequence was renumbered afterwards.
2. “TB-500 is thymosin beta-4.” Not reliably. Thymosin beta-4 is a 43-residue peptide (44 with the initiator methionine), and “TB-500” is used both for synthetic full-length thymosin beta-4 and for short fragments of it, so the two literatures are not interchangeable unless the molecule in the vial is identified.
3. “ERK is phosphorylated at Thr202/Tyr204.” That is ERK1 numbering. ERK2’s equivalent sites are Thr185/Tyr187, and rat ERK2 is Thr183/Tyr185.
4. “There are three MAPK pathways.” Four classic cascades, counting ERK5, plus atypical MAPKs that skip the three-tier architecture entirely.
5. “KSR is just a scaffold.” It was named a kinase, reclassified as a pseudokinase, and then shown — for the KSR2 isoform — to bind ATP and phosphorylate MEK1, with BRAF allosterically stimulating it through a side-to-side dimer. Neither “only a scaffold” nor “a conventional kinase” is right.
6. “PD98059 and U0126 are ERK inhibitors.” They are MEK inhibitors acting upstream. Every experiment using them demonstrates MEK-dependence, not direct ERK involvement, and they do not distinguish ERK1 from ERK2.
7. “ERK activation means proliferation.” Duration encodes the outcome, not presence — the same kinase gives different fates, with c-Fos as the sensor that reads the difference.

What’s settled and what isn’t

Sourcing signalling reagents in Canada

If you are buying reagents for signalling work, the documentation questions are the usual ones, with one that is specific to this field.

• Check identity, not just purity. A phospho-Western readout is only as good as the certainty that the vial contains what the label says. See our guides to HPLC testing and LC-MS.
• Match the batch number on the certificate to the one on your vial; a report for another lot is a specification sheet.
• Account for net peptide content when you calculate a molar concentration, because lyophilized peptide arrives as a salt carrying counter-ions and water. The net peptide content guide works through it.
• Check what the literature on your compound actually measured before you design around a mechanism. The table above is the short version for this pathway.

IGF-1 LR3IGF-1 receptor signalling through the MEK–ERK arm is the clearest published link on this pageView product MOTS-cA narrow, cell-type-dependent ERK result — positive in one myoblast line, absent in anotherView product BPC-157One in-vitro study, one cell type, with the caveats set out aboveView product

Frequently asked questions